Drug Patents owned by Axsome Malta

1. Drug name - SUNOSI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in